Retatrutide and type 1 diabetes is an emerging area of scientific interest, though the evidence base remains at a very early stage. Retatrutide is an investigational triple receptor agonist developed by Eli Lilly, targeting GLP-1, GIP, and glucagon receptors simultaneously. Whilst Phase 2 trials have demonstrated significant metabolic effects in adults with obesity and type 2 diabetes, no published randomised controlled trials have included people with type 1 diabetes. This article outlines what is currently known, the potential risks, the UK regulatory position, and how to have informed conversations with your diabetes care team.
Summary: Retatrutide has not been studied in type 1 diabetes clinical trials and is
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Heading 6
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.
Block quote
Ordered list
- Item 1
- Item 2
- Item 3
Unordered list
- Item A
- Item B
- Item C
Bold text
Emphasis
Superscript
Subscript
